Supraventricular tachydysrhythmias (SVTs) are a common presenting complaint, with a national prevalence of 3/1000 persons. While most commonly stable, prolonged paroxysms can deteriorate into haemodynamically unstable subtypes or ventricular dysrhythmias. Early recognition with appropriate management is critical to reducing the morbidity associated with this condition. The American Heart Association holds that vagal manoeuvres are a first-line therapy in the management algorithm of stable SVTs. However, they state that no clear recommendations can be made around which manoeuvre to use, highlighting that future research should examine the efficacy and safety profiles of the various manoeuvres. In the South African primary care setting, clinicians must be at the forefront of pragmatic management strategies in the face of resource limitations, such as the unavailability of adenosine – a second-line therapy when vagal manoeuvres fail. In this article, we begin with a case study and review the literature around vagal manoeuvres.
family medicineprimary carerural medicinesupraventricular tachycardiavagal manoeuvreCase studyPresentation
A 35-year-old man presented to our centre during a weekend shift. He reports a 2-h history of experiencing palpitations and anxiety. The symptoms had begun at around 4 o’clock in the afternoon after a Sunday lunch with his family. He had drunk four units of alcohol over a 3-h period and smoked three cigarettes earlier that day.
Past medical
He reported two previous episodes at 29 years and 33 years of age. During the previous episodes, inpatient workup had ruled out any metabolic and/or endocrinological abnormalities, as well as structural heart disease (by electrocardiography [ECG] and echocardiography). He is currently awaiting his cardiology outpatient appointment date. He has no chronic medical illnesses and had an appendectomy at 13 years of age. There was no family history of cardiac disease.
Social
He reports occasional alcohol use of around four units of alcohol per weekend, with no use during the week. He is not a regular smoker, smoking up to five cigarettes in a month. The patient did not use any illicit substances and drank three cups of coffee per day. He resides in a four-room house with his life partner of 6 years. Both are employed, have stable jobs, and he reports no psychosocial stressors.
Examination
The patient’s observations were as follows:
Blood pressure (BP): 135/85
Pulse: 215 beats per minute
Saturation: 96% (room air)
Respiratory rate: 22
Examination reveals good peripheral perfusion with a regular tachycardia. Air entry was equal bilaterally, without adventitious sounds. There was no lower limb oedema or jugulovenous distension. The liver was not palpable.
This patient was assessed as having a stable supraventricular tachycardia (SVT). He was moved to the high care area in the emergency centre, placed on monitors, baseline bloods were drawn and an ECG was done that showed a regular, narrow complex tachycardia, similar to the ECG in Figure 1.1
Electrocardigraph (ECG) example of narrow complex supraventricular tachydysrhythmias.
A modified Valsalva manoeuvre was performed and normal sinus rhythm was restored. A post-reversion ECG was unremarkable.
Background
Tachydysrhythmias are defined as abnormal heart rhythms with a ventricular rate above 100 beats per minute.2 Supraventricular tachydysrhythmias are dysrhythmias that originate at, or above, the level of the His-Purkinje system3 from either atrial tissue or the atrioventricular (AV) junction:
Supraventricular tachydysrhythmias are most commonly narrow complex tachydysrhythmias but can have broad complexes when there is pre-existing aberrant conduction (e.g. bundle branch blocks), tachycardia-induced aberrancy (physiological), or, in the case of an accessory pathway, with antidromic conduction.
While local literature on the incidence of SVT is sparse, evidence shows that the national prevalence approximates international figures at around 3/1000 persons.4 The majority of SVTs are because of re-entry pathways, without the presence of underlying cardiac disease.3 Common symptoms include syncope/presyncope, palpitations, shortness of breath, diaphoresis, chest pain and lightheadedness/dizziness.
An approach
Most cases of SVT are stable unless there is an underlying cardiac failure, ischaemia or other co-morbidities (such as sepsis or toxin ingestion).
Determining the haemodynamic stability of the patient is the first step in evaluation. A useful mnemonic for this is HASIA:
If any of these cues are present, attempt to rapidly rule out sinus tachycardia3 (and treat the underlying cause). If this is ruled out, immediate synchronised cardioversion according to Advanced Cardiac Life Support principles is warranted.
Provided there are no emergent signs or symptoms that warrant synchronised cardioversion, we regard the SVT as stable and proceed with the evaluation of the SVT:3
Is it regular or irregular?
Are P waves discernible? If so, what is their morphology?
Perform the Valsalva maneuver!!:
The American Heart Association describes vagal manoeuvres as a class one recommendation (level of evidence B-R) for first-line therapy of stable SVTs,3 although they note that vagal manoeuvres require further refinement to establish their effectiveness and safety.3
Which vagal manoeuvre is best?
Studies have recurrently shown the Valsalva manoeuvre (VM) as superior to other options in adults:
The diving reflex can be technically challenging and is not frequently employed in adults. In children, eliciting the diving reflex by use of a cold water bucket is supported as a first choice intervention by high quality evidence.3 While the carotid sinus massage is the simplest to perform, studies have reported iatrogenic peril (thromboembolic stroke from dislodged carotid atheroma) in around 1% of cases.7 The greater effectiveness and improved risk profile of the VM have seen it become a first choice vagal manoeuvre for the treatment of stable SVT in adult patients There are several challenges around the use of adenosine in the primary care setting that limit its use (see Box 1).
What about adenosine?
The pharmacokinetics of adenosine make it a highly favourable agent5:
Rapid onset
Short half-life (< 10 seconds)
Highly selective for adenosine-1 receptor:
A1 receptor – induces asystole by inhibiting adenylyl cyclase and reducing intracellular cAMP, which hyperpolarizes cardiac cells by increasing K+ efflux (in turn inhibiting Ca2+ and B-agonist receptors)4
Rapid intracellular metabolism
However, the adverse effects of adenosine include a high incidence of new and transient cardiac arrhythmia (up to 55%), dyspnoea (12% – 28%), chest tightness (40%), dizziness (< 12%), headache, facial flushing (44%), nausea and an ‘electric shock’ sensation.6
Contraindications include hypersensitivity, high-grade heart block, sick sinus rhythm, bronchoconstrictive or bronchospastic disease, including asthma.6
The success of adenosine is dependent on several technical factors such as the proximity of venous access to heart, elevation of the limb and the rapid use of saline flush with a three-way stop cock.
Note: In South Africa, adenosine is not available at community health centres or clinics. It is not found in the essential drug list and is not mentioned as a step in the management of tachydysrhythmias in the standard treatment guidelines.6
A recent modification to the VM was employed in the landmark REVERT trial (see Tables 1 and 2), which showed increased sinus reversion rates (compared to the conventional VM) and no increase in harm Subsequent trials have validated these findings.11
The REVERT trial – Primary and secondary outcomes.
Outcome
Standard VM
Modified VM
Effect size
n (214)
%
Median
IQR
n (214)
%
Median
IQR
OR
95% CI
Median
IQR
p
Presence of sinus rhythm at 1 min
37
17
-
-
93
43
-
-
3.7
2.3–5.8
-
-
< 0.0001
Adenosine needed
148
69
-
-
108
50
-
-
0.45
0.30–0.68
-
-
0.0002
Any other emergency anti-arrhythmic needed
171
80
-
-
121
57
-
-
0.33
0.21–0.51
-
-
< 0.0001
Discharged home from emergency room
146
68
-
-
134
63
-
-
0.79
0.51–1.21
-
-
0.28
Any adverse events
8
4
-
-
13
6
-
-
1.61
0.63–4.08
-
-
0.32
Time spent in emergency room (h)
-
-
2.83
1.05–3.62
-
-
2.82
1.95–3.77
-
-
0.90
0.75–1.10
0.31
Source: Adapted from Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): A randomised controlled trial. Lancet. 2015;386(10005):1747–1753. https://doi.org/10.1161/01.CIR.98.24.2716
Source: Adapted from Appelboam A, Reuben A, Mann C, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): A randomised controlled trial. Lancet. 2015;386(10005):1747–1753. https://doi.org/10.1161/01.CIR.98.24.2716
VM, Valsalva manoeuvre.
, Transient headache (n = 2); shortness of breath (n = 1); cyanosis (in different patients; n = 1);
, Transient chest wall pain on straining.
The physiology behind the Valsalva manooeuvre
Conceptually, the aim of the VM is to induce a cascade of four phases vagotonic fluxes that incrementally increase until sufficient vagal tone to induce AV nodal blockade is achieved (see Figure 2).
The physiology of the Valsalva manoeuvre.
Phase I:
Increased intrathoracic pressure – systolic blood pressure (SBP) rises (> 15 mmHg) following initiation of Valsalva (10 s)
Triggers baroreceptor reflex (either at a carotid bifurcation or within aortic arch)
Afferent impulses via glossopharyngeal (carotid) or vagus (aortic) nerve to vagal nuclei within nucleus tractus solitarius within the medulla
Phase II:
Decreased venous return; increased systemic arterial pressure; blood pressure return to (just below) normal while a strain is maintained
Efferent impulses from vagal nuclei descend both right and left vagal nerves to heart, lungs and gastrointestinal tract.
Right vagus nerves stimulate sinoatrial (SA) node – decreased firing
Left vagus innervates av node – decreased conduction
Phase III:
Decreased intrathoracic pressure. Blood pressure drops when strain is released.
Phase IV:
Rapid increase in BP as sympathetic surge response to decreased systolic pressure.
The response to the hypotension induced by the VM is the final means by which we induce a strong vagal tone to terminate the tachydysrhythmia.
The purpose of a vagal manoeuvre is to impact cardiac physiology. The desired effects are mostly achieved in phases I and IV:10
SA node – slowed impulse generation in SA node.
Atria – normal conduction velocity; prolonged refractory period.
AV node – decreased conduction in AV node with prolonging of the refractory period.
Ventricles – decreased inotropy; normal conduction in His-Purkinje system.
When should we use the VM?
Therapeutic – Haemodynamically stable patients: first-line therapy of SVT.
Diagnostic – May help distinguish SVT from VT by slowing conduction.
As mentioned, the most profound vagotonic effects are induced at the SA and AV nodes, and hence these rhythms undergo the highest reversion success rates. Figure 3 provides an approach to the patient presenting with stable SVT and three clinical scenarios (A, B and C):
A – Vagal manoeuvres can terminate tachycardias of atrial origin, but they have a lower success rate and care must be taken to not perform AV node blockade in wide-complex tachycardias or if the patient has a known accessory pathway (risk of inducing ventricular fibrillation).
B – Vagal manoeuvres are most successful in AV nodal-dependent SVTs (AVRT and AVNRT). At this stage, the clear dichotomy between therapeutic effect (reversion to sinus rhythm) and diagnostic application (slowing the rate to discern the dysrhythmia present and determine the best management approach) can be noted.
C – If p waves are present and can be characterised, either can vagal manoeuvres be tried or an effective therapeutic agent selected based on the type of rhythm.
Evaluation of supraventricular tachydysrhythmias.
How to perform the modified Valsalva
Equipment:
12 lead ECG placed on patient
Cardiac monitoring – continuous
Pulse oximetry
Non-invasive BP monitoring – cycling frequently
Intravenous access with fluids either running or immediately available
Resuscitation trolley available
Airway
Oxygen
Crash cart with appropriate antiarrhythmic available and procedural sedation should cardioversion be required
Staff:
Lead clinician
Nursing assistant for monitoring
If available, use an assistant to elevate legs
An informed, cooperative patient is paramount. The American Heart Association advocates teaching a patient to cough on command (vagotony from coughing terminates a bradycardia consequent to the Valsalva).3
Technique:9
Attach all monitors, have support staff.
Patient is seated in an upright seated position.
Patient blows against a 10 mL syringe to move plunger (approximately 30–40 mmHg) for 10–20 s
Immediately drop patient to supine position
Simultaneously elevate patient’s legs to 45° – 90°
Hold for 45–60 s
Repeat if necessary
The ‘modification’ of the Valsalva by dropping the head of the patient, elevating the legs, and finally lifting the head of the patient accentuates the physiological effects of the Valsalva manoeuvre – increasing the likelihood of success.
Clinical bottom line and applicability to the patient
Supraventricular tachydysrhythmias are the most common tachyarrhythmias with an incidence of 3/1000 persons. Most SVTs are benign conditions without underlying structural heart pathology. However, their propensity to deteriorate into unstable SVTs or ventricular fibrillation mandates early and effective treatment. The modified VM is the most effective vagal manoeuvre with minimal documented adverse effects and should be used as the first-line therapy in the management of SVT.
The patient in our case study was a 35-year-old man who presented with a recurrent, stable AVNRT in the absence of any underlying structural heart disease. The effective management of his AVNRT avoided unnecessary admission to a higher level of care while awaiting his outpatient cardiology appointment. This case highlights the value of evidence-based practice in the primary care setting to provide appropriate care while avoiding unnecessary medical intervention with its associated costs and potential harm.
AcknowledgementsCompeting interests
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.
Authors’ contributions
S.D.M. was responsible for conceptualisation and the original draft. M.T. was responsible for review and editing.
Ethical considerations
This article followed all ethical standards for research without direct contact with human or animal subjects.
Funding information
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Data availability
Data sharing is not applicable to this article as no new data were created or analysed in this study.
Disclaimer
The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any affiliated agency of the authors.
ReferencesBurnsE, ButtnerR. Supraventricular Tachycardia (SVT) [serial online]. Life in the Fast Lane (LITFL). 2020[cited 2021 Dec 14]. Available from: https://litfl.com/supraventricular-tachycardia-svt-ecg-library/LindbergDM. Modified Valsalva maneuver for Supraventricular Tachycardia. NEJM J Watch Emerg Med Walth [serial online]. 2015[cited 2019 Apr 3]. Available from: https://search.proquest.com/docview/1707983466/abstract/941C07D98BA84E65PQ/21PageRL, JoglarJA, CaldwellMA, et al. ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia. Circulation. 2016;133(14):e506–e574. https://doi.org/10.1161/CIR.0000000000000311BonnyA, NgantchaM, ScholtzW, et al. Cardiac arrhythmias in Africa. J Am Coll Cardiol. 2019;73(1):100–109. https://doi.org/10.1016/j.jacc.2018.09.084SmithG. Management of supraventricular tachycardia using the Valsalva manoeuvre: A historical review and summary of published evidence. Eur J Emerg Med. 2012;19(6):346–352. https://doi.org/10.1097/MEJ.0b013e32834ec7adLimSHC, LaiSM, WongKCK. Head down deep breathing for cardioversion of paroxysmal supraventricular tachycardia. Case Rep Emerg Med. 2018;2018:1–3. https://doi.org/10.1155/2018/1387207CollinsNA, Higgins IIIGL. Reconsidering the effectiveness and safety of carotid sinus massage as a therapeutic intervention in patients with supraventricular tachycardia. Am J Emerg Med. 2015;33(6):807–809.WenZC, ChenSA, TaiCT, ChiangCE, ChiouCW, ChangMS. Electrophysiological mechanisms and determinants of vagal maneuvers for termination of paroxysmal supraventricular tachycardia. Circulation. 1998;98(24):2716–2723. https://doi.org/10.1161/01.CIR.98.24.2716AppelboamA, ReubenA, MannC, et al. Postural modification to the standard Valsalva manoeuvre for emergency treatment of supraventricular tachycardias (REVERT): A randomised controlled trial. Lancet. 2015;386(10005):1747–1753. https://doi.org/10.1161/01.CIR.98.24.2716PstrasL, ThomasethK, WaniewskiJ, BalzaniI, BellavereF. The Valsalva manoeuvre: Physiology and clinical examples. Acta Physiol Oxf Engl. 2016;217(2):103–119. https://doi.org/10.1111/apha.12639PallinDJ. Modified Valsalva maneuver increases conversion of paroxysmal supraventricular tachycardia. NEJM J Watch Emerg Med Walth [serial online]. 2017[cited 2019 Apr 3]; Available from: https://search.proquest.com/docview/1907733598/abstract/941C07D98BA84E65PQ/25
How to cite this article: Murphy SD, Torlutter M. The use of vagal manoeuvres in narrow complex tachyarrhythmias in primary care. S Afr Fam Pract. 2022;64(1), a5413. https://doi.org/10.4102/safp.v64i1.5413